Ascend Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

Ascend Capital’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,126	Closed	-$943K	–	216
2017 Q3	$943K	Sell	10,126 -151,508	-94%	-$13.4M	0.04%	152
2017 Q2	$14.7M	Buy	+161,634	New	+$14.7M	0.68%	51
2017 Q1	–	Sell	-85,610	Closed	-$7.09M	–	143
2016 Q4	$7.09M	Buy	+85,610	New	+$7.36M	0.35%	82
2015 Q1	–	Sell	-20,000	Closed	-$1.81M	–	173
2014 Q4	$1.81M	Sell	20,000 -140,650	-88%	-$11.7M	0.07%	147
2014 Q3	$11.6M	Buy	160,650 +107,650	+203%	+$7.07M	0.34%	98
2014 Q2	$3.3M	Buy	+53,000	New	+$3.2M	0.11%	148

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ascend Capital's BMRN Position: Q4 2017 in Review

Ascend Capital sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2017, closing a stake of 10,126 shares — an estimated $943K sold.

Ascend Capital first reported a position in BMRN in Q2 2014 and held it in 6 quarters. The position peaked at $14.7M in Q2 2017. 438 funds tracked by Wall St. Rank hold BMRN as of Q4 2017.

Ascend Capital reported no remaining BioMarin Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Ascend Capital sold 10,126 BioMarin Pharmaceuticals shares in Q4 2017, an estimated $943K.
Ascend Capital first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 6 quarters.
Ascend Capital's BioMarin Pharmaceuticals position peaked at $14.7M in Q2 2017.
438 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2017.

Based on Ascend Capital's 13F filing for Q4 2017, filed 13 Feb 2018.